Rasburicase Market
Number of pages: 100 | Report Format: PDF | Published date: June 19, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
6.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Indication, Patient Type, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global rasburicase market is expected to register a revenue CAGR of 6.5% in the forecast period.
Rasburicase Market Fundamentals
Rasburicase is recommended to treat increased uric acid in patients receiving chemotherapy for leukemia, lymphoma, or solid tumors likely to experience tumor lysis and raised uric acid levels. Rasburicase is produced from a cDNA coding from a modified Aspergillus flavus strain and expressed in a modified yeast strain of Saccharomyces cerevisiae. Rasburicase, a recombinant urate oxidase enzyme, changes existing uric acid into allantoin, 5–10 times more soluble in urine than uric acid. Rasburicase differs from allopurinol because it can alter the plasma uric acid already there. In contrast, allopurinol only inhibits the formation of uric acid in the future by inhibiting xanthine oxidase. Rasburicase converts uric acid to allantoin, releasing carbon dioxide and hydrogen peroxide.
The prevalence of tumor lysis syndrome in adults is poorly understood and might appear suddenly. Rasburicase is the most modern method for preventing and treating tumor lysis syndrome, among many others. The Food and Drug Administration has authorized rasburicase in patients at risk of suffering tumor lysis syndrome or for treating high uric acid levels. Rasburicase is efficient in clinical studies in both pediatric and adult populations. Rasburicase has an elimination half-life of between 16 and 21 hours when given at doses of 0.15 mg/kg and 0.2 mg/kg, respectively. Rasburicase is broken down by peptide hydrolysis. Therefore clearance is independent of renal and hepatic function. No conclusive evidence can be offered for the adult and geriatric populations due to the limited pharmacokinetic evaluation in these populations. Additionally, the buildup of dangerous plasma levels of purine metabolites, such as uric acid, is frequently caused by medications used to treat lymphoid leukemia, non-Hodgkin's lymphoma, and acute myelogenous leukemia. Rasburicase administration lowers uric acid levels and lessens the toxicity of chemotherapy-induced tumor lysis.
Rasburicase Market Dynamics
The increasing prevalence of non-Hodgkin lymphoma (NHL), solid tumor malignancies, and the demand for novel treatments and technologies are propelling the market's growth. According to a research report released in February 2021 and titled "Epidemiology, Pathology, and Clinical Features of DLBCL," diffuse large B-cell lymphoma (DLBCL), which accounts for around 31% of adult cases, is the most prevalent NHL in Western nations. BL (2% of instances) and Mantle Cell Lymphoma (6% of cases) are two more prevalent aggressive B-cell subtypes. Marginal zone lymphoma (MZL) (8% of cases), chronic lymphocytic leukemia (CLL), and FL account for the majority of indolent B-cell NHL cases in the Western world, chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL) (6% of cases) and lymphoplasmacytic lymphoma (LPL) (1% of cases).
Numerous governmental and nongovernmental groups, including the American Cancer Society, the National Cancer Institute (NCI), and the Foundation for the National Institutes of Health, have organized diagnostic campaigns and taken on projects to find ALL. In addition, the "Therapeutically Applicable Research to Generate Effective Treatments (TARGET)" initiative and the "Childhood Cancer Targeted Therapeutics Workshop" have launched numerous programs and worked with numerous research institutions across various nations, including St. Jude Children's Research Hospital and University of New Mexico, among others, to offer patients facilities for an earlier diagnosis and better leukemia treatment.
Numerous governmental and nongovernmental groups, including the American Cancer Society, the National Cancer Institute (NCI), and the Foundation for the National Institutes of Health, have organized diagnostic campaigns and taken on projects to find ALL. In addition, the "Therapeutically Applicable Research to Generate Effective Treatments (TARGET)" initiative and the "Childhood Cancer Targeted Therapeutics Workshop" have launched numerous programs and worked with numerous research institutions across various nations, including St. Jude Children's Research Hospital and University of New Mexico, among others, to offer patients facilities for an earlier diagnosis and better leukemia treatment.
However, despite the benefits of rasburicase medicine, unpleasant reactions and side effects linked to the goods are expected to restrain the growth of the worldwide market. Various therapies can result in undesirable effects, including severe hypersensitive responses like anaphylaxis. It should stop being given to any patient with clinical signs of a severe hypersensitivity response immediately and permanently.
When given to individuals with G-6-PD deficiencies, this medication can potentially result in serious hemolysis. It should be stopped right away and permanently if a patient starts to have hemolysis. Before beginning rasburicase, it is advised that individuals are more likely to have G-6-PD deficiency (such as those of African or Mediterranean heritage) be tested. Methemoglobinemia has been linked to the usage of rasburicase. Any patient who develops methemoglobinemia should have their treatment stopped promptly and permanently.
Rasburicase Market Ecosystem
The global rasburicase market is analyzed from the following perspectives: indication, patient type, and region.
Rasburicase Market by Indication
Based on the indication, the global rasburicase market is segmented into leukemia, lymphoma, solid tumor malignancies, and others.
The leukemia segment will likely grow at a significant revenue CAGR during the forecast period. The rising prevalence of leukemia is driving the market segment. For instance, In the US, 186,400 individuals are anticipated to receive leukemia, lymphoma, or myeloma diagnosis in 2021. The anticipated 1,898,160 new cancer cases diagnosed in the US in 2021 will include 9.8% of new leukemia, lymphoma, and myeloma cases. The projected number of persons diagnosed with the disease and still living in a community on a certain date is known as the prevalence. In the US, an estimated 1,519,907 persons have leukemia, lymphoma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPNs) and are remission.
Additionally, on average, patients with blood cancer die in the US every 9 minutes. More than six people each hour, or over 158 persons per day, are represented by this number. In the US, an estimated 57,750 individuals will die from leukemia, lymphoma, and myeloma in 2021. Based on the predicted number of 608,570 cancer deaths in 2021, these disorders are anticipated to cause 9.5% of cancer-related fatalities.
Rasburicase Market by Patient Type
The global rasburicase market is segmented based on the patient type into adult and pediatric.
The adult patient type will likely dominate the market during the forecast period. When compared to the current standard of treatment (oral allopurinol), Elitek (Rasburicase) dramatically decreased plasma uric acid (PUA) levels in adults with hematologic malignancies who were at risk for the potentially fatal consequence of tumor lysis syndrome (TLS). A malignancy-related increase in PUA (hyperuricemia) or a diagnosis of a particularly aggressive hematologic malignancy (lymphoma or leukemia) were the two conditions that defined patients at high risk for TLS. Elitek has been approved for use in adult cancer patients, giving medical professionals an effective new alternative for treating high plasma uric acid levels that could cause tumor lysis syndrome, a potentially fatal side effect of chemotherapy for cancer.
Rasburicase Market by Region
Based on the region, the global rasburicase market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The high incidence and awareness of many kinds of cancer, including various types of blood malignancies like non-Hodgkin's lymphoma, Leukemia, etc., contributed to North America's supremacy worldwide. Such patterns have prompted pricey drugs like Rasburicase to treat several lymphomas. Additionally, Non-Hodgkin lymphoma (NHL), which makes up around 4% of all cancer cases in the country, is one of the most prevalent malignancies. According to the American Cancer Society's forecasts, there will be roughly 80,470 cases of non-Hodgkin's lymphoma in March 2022 (44,120 men and 36,350 women) in children and adults are included in this. This malignancy will claim the lives of around 20,250 people (11,700 men and 8,550 women). In general, the likelihood that someone would acquire NHL in their lifetime is around 1 in 42; for women, the risk is approximately 1 in 52. As a result, such a rise in the target population will probably aid in regional development.
During the projection period, it is expected that the markets in Europe and Asia-Pacific will account for a sizeable portion of the worldwide market. Leukemia treatment and symptom awareness are highly prevalent in Europe, which is anticipated to promote market expansion. For instance, the most prevalent acute leukemia in adults is acute myeloid leukemia, affecting 5/100,000 people in Europe, or more than 20,000 new cases yearly. In addition, Lithuania recorded the European average of 20.4 new cases of leukemia per 100,000 people. An incidence rate of 18.9 cases per 100,000 people in Belgium followed this. In contrast, that year, 18.5 leukemia cases per 100,000 people were recorded in France.
Rasburicase Market Competitive Landscape
Some of the prominent market players in the global rasburicase market include,
Rasburicase Market Strategic Development
Rasburicase is recommended to treat increased uric acid in patients receiving chemotherapy for leukemia, lymphoma, or solid tumors likely to experience tumor lysis and raised uric acid levels.
North America region dominated the global rasburicase market in 2022.
The revenue CAGR of the rasburicase market during the forecast period will be 6.5%
Some prominent market players in the global rasburicase market include Sanofi S.A., Manus Aktteva Biopharma LLP, and Trumac Healthcare.
The adult segment led the global rasburicase market in 2022.
*Insights on financial performance are subject to the availability of information in the public domain